First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers

Mechanisms of resistance to immune checkpoint inhibitors

(2018) Russell W Jenkins et al.   BRITISH JOURNAL OF CANCER

Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma

(2018) Yusheng Cheng et al.   Cell Death & Disease

Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade

(2017) Esra A. Akbay et al.   Journal of Thoracic Oncology

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity

(2017) Shabnam Shalapour et al.   NATURE

JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer

(2017) Chunwan Lu et al.   OncoImmunology

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression

(2017) Georgina V. Long et al.   JAMA Oncology

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia

(2016) Howard A. Liebman et al.   HAEMATOLOGICA

The re-polarisation of M2 and M1 macrophages and its role on cancer outcomes

(2016) Nicoline Y. den Breems et al.   JOURNAL OF THEORETICAL BIOLOGY

Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia

(2016) Howard A. Liebman et al.   HAEMATOLOGICA

STAT3 inhibition for cancer therapy: Cell-autonomous effects only?

(2016) Guido Kroemer et al.   OncoImmunology

Peritumoral stromal neutrophils are essential for c-Met-elicited metastasis in human hepatocellular carcinoma

(2016) Min He et al.   OncoImmunology

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

(2016) Shruti Agrawal et al.   Journal for ImmunoTherapy of Cancer

PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment

(2016) Tomoaki Iwata et al.   Scientific Reports

Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches

(2015) Tim F Greten et al.   GUT

Erratum: Advances in targeted therapies for hepatocellular carcinoma in the genomic era

(2015) Josep M. Llovet et al.   Nature Reviews Clinical Oncology

Big opportunities for small molecules in immuno-oncology

(2015) Jerry L. Adams et al.   NATURE REVIEWS DRUG DISCOVERY

Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases

(2014) A Saied et al.   CANCER GENE THERAPY

Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma

(2014) B. Hu et al.   CLINICAL CANCER RESEARCH

Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design

(2014) J. M. Llovet et al.   CLINICAL CANCER RESEARCH

Duration of Stable Disease Is Associated with Overall Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

(2014) Tadaaki Arizumi et al.   DIGESTIVE DISEASES

Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions

(2014) Tai Hato et al.   HEPATOLOGY

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

(2014) Arnoud J. Templeton et al.   JNCI-Journal of the National Cancer Institute

Platelet-Related Phenotypic Patterns in Hepatocellular Carcinoma Patients

(2014) Brian I. Carr et al.   SEMINARS IN ONCOLOGY

Macrophage Regulation of Tumor Responses to Anticancer Therapies

(2013) Michele De Palma et al.   CANCER CELL

Cytokine patterns in patients with cancer: a systematic review

(2013) Bodo E Lippitz   LANCET ONCOLOGY

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

(2013) John J. O'Shea et al.   NEW ENGLAND JOURNAL OF MEDICINE

A new therapeutic strategy for malaria: targeting T cell exhaustion

(2012) Gordon J Freeman et al.   NATURE IMMUNOLOGY

Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions

(2011) Junmin Zhou et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Icaritin Shows Potent Anti-Leukemia Activity on Chronic Myeloid Leukemia In Vitro and In Vivo by Regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT Signalings

(2011) Jian feng Zhu et al.   PLoS One

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY